درمان آرتریت روماتوئید با سلول‌های بنیادی/استرومایی مزانشیمال: مروری بر کارآزمایی‌های بالینی

نوع مقاله : مقاله مروری

نویسندگان

1 استادیار، گروه علوم آزمایشگاهی، دانشکده‌ی پیراپزشکی، دانشگاه علوم پزشکی تربت حیدریه، تربت حیدریه، ایران

2 کارشناس ارشد، گروه علوم آزمایشگاهی، دانشکده‌ی پیراپزشکی، دانشگاه علوم پزشکی تربت حیدریه، تربت حیدریه، ایران

3 استاد، گروه ایمونولوژی، مرکز تحقیقات فارماکولوژیک گیاهان دارویی، دانشگاه علوم پزشکی مشهد، مشهد، ایران

10.48305/jims.v43.i822.0804

چکیده

مقاله مروری




مقدمه: آرتریت روماتوئید (Rheumatoid Arthritis) RA بیماری خودایمنی التهابی با هیپرپلازی سینوویال و تولید اتوآنتی‌بادی‌هایی است که بافت مفصل، غضروف و برخی بافت‌های بدن را هدف قرار می‌دهند که در نهایت به تخریب استخوان و غضروف منجر می‌شود. درمان‌های متداول RA تنها درد و التهاب را کاهش می‌دهند اما بافت آسیب‌دیده‌ را ترمیم نمی‌کنند. همچنین، عوارض جانبی و مقاومت دارویی مرتبط با درمان‌های متداول در برخی بیماران RA گزارش‌شده است؛ در نتیجه، پیش‌آگهی ضعیف بیماری و عدم وجود درمان قطعی، محققان را بر آن داشته است تا گزینه‌های درمانی جایگزین را بررسی کنند. سلول‌های بنیادی مزانشیمی (Mesenchymal Stem Cells) MSCs یکی از این رویکردهای درمانی امیدوارکننده هستند.
روش‌ها: اثرات درمانی MSCs در فازهای مختلف تحقیقات از جمله کارآزمایی‌های بالینی متعدد مورد بررسی قرار گرفته است. هدف این مطالعه‌ی مروری، بررسی و ارائه اثرات ایمنی درمان RA با استفاده از MSCs، بر اساس مطالعات منتشر شده در پایگاه‌های اطلاعاتی Web of Science و PubMed در ۱۵ سال گذشته می‌باشد.
یافته‌ها: نتایج مطالعات مختلف نشان می‌دهد که MSCs می‌توانند با تنظیم پاسخ‌های سیستم ایمنی، به طور مؤثری التهاب را کاهش داده و درد را در بیماران RA تسکین دهند.
نتیجه‌گیری: با توجه به عوارض جانبی مرتبط با درمان‌های متداول RA و مقاومت دارویی که در برخی بیماران مشاهده می‌شود، درمان‌های جایگزین مانند MSCs ممکن است فرصت‌های جدیدی برای مدیریت و درمان این بیماری ارائه دهند.

تازه های تحقیق

محسن قریانی:Google Scholar, PubMed

فائزه باقری فر: Google Scholar

مژگان محمدی: Google Scholar, PubMed

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

Mesenchymal Stem/Stromal Cell Therapy in Rheumatoid Arthritis: A Review of Clinical Trials

نویسندگان [English]

  • Mohsen Ghoryani 1
  • Faeze Bagherifar 2
  • Mojgan Mohammadi 3
1 Assistant Professor, Department of Laboratory Sciences, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
2 MSc, Department of Laboratory Sciences, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
3 Professor, Department of Immunology, Pharmacological Research Center of Medical Plants, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده [English]

Background: Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by synovial hyperplasia and the production of autoantibodies that target joint tissues, cartilage, and other bodily structures, ultimately leading to the destruction of bone and cartilage. Conventional therapies for RA only relieve pain and inflammation but do not repair damaged tissue. Furthermore, side effects and drug resistance associated with these conventional treatments have been reported in some RA patients. Consequently, the poor prognosis of the disease and the lack of a definitive cure have prompted researchers to explore alternative treatment options. Mesenchymal stem cells (MSCs) represent one such promising therapeutic approach.
Methods: The therapeutic effects of MSCs have been evaluated in various research phases, including numerous clinical trials. This review aims to examine and present the immunological effects of MSC-based treatment for RA, based on studies published in the Web of Science and PubMed databases over the past 15 years.
Findings: The results of various studies indicate that MSCs can effectively reduce inflammation and alleviate pain in patients with RA by modulating immune system responses.
Conclusion: Considering the side effects associated with conventional therapies for RA and the drug resistance observed in some patients, alternative therapies such as MSCs may offer new opportunities for the management and treatment of this disease.

کلیدواژه‌ها [English]

  • Rheumatoid arthritis
  • Mesenchymal Stem cells
  • Immune system

مراجع

  1. Weddell J, Hider S. Diagnosis and management of rheumatoid arthritis. Prescriber 2021; 32(10): 15-20.
  2. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 2010; 62(6): 1576-82.
  3. Wasserman A. Rheumatoid arthritis: common questions about diagnosis and management. Am Fam Physician 2018; 97(7): 455-62.
  4. Inchingolo F, Inchingolo AM, Fatone MC, Avantario P, Del Vecchio G, Pezzolla C, et al. Management of Rheumatoid Arthritis in Primary Care: A Scoping Review. Int J Environ Res Public Health 2024; 21(6): 662.
  5. Motta F, Bizzaro N, Giavarina D, Franceschini F, Infantino M, Palterer B, et al. Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis. RMD Open 2023; 9(3): e002817.
  6. Kiely PD, Nikiphorou E. Management of rheumatoid arthritis. Medicine 2018; 46(4): 216-21.
  7. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol 2017; 31(1): 3-18.
  8. Shimizu Y, Ntege EH, Azuma C, Uehara F, Toma T, Higa K, et Management of Rheumatoid Arthritis: Possibilities and Challenges of Mesenchymal Stromal/Stem Cell-Based Therapies. Cells 2023; 12(14): 1905.
  9. Mueller A-L, Payandeh Z, Mohammadkhani N, Mubarak SM, Zakeri A, Alagheband Bahrami A, et al. Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells 2021; 10(11): 3017.
  10. Padyukov L. Genetics of rheumatoid arthritis. Semin Immunopathol 2022; 44: 47-62.
  11. Dedmon LE. The genetics of rheumatoid Rheumatology (Oxford) 2020; 59(10): 2661-70.
  12. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers 2013; 35(6): 727-34.
  13. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity 2017; 46(2): 183-96.
  14. Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Ghoryani M, Mohammadi M. A significant decrease of BAFF, APRIL, and BAFF receptors following mesenchymal stem cell transplantation in patients with refractory rheumatoid Gene 2020; 732: 144336.
  15. Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 2020; 9(4): 880.
  16. Kubo S, Nakayamada S, Tanaka Y. JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs 2023; 32(4): 333-44.
  17. Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol 2019; 15(1): 9-17.
  18. Isacco CG, Ballini A, De Vito D, Nguyen KC, Cantore S, Bottalico L, et al. Rebalancing the oral microbiota as an efficient tool in endocrine, metabolic and immune disorders. Endocr Metab Immune Disord Drug Targets 2021; 21(5): 777-84.
  19. Inchingolo F, Inchingolo AM, Avantario P, Settanni V, Fatone MC, Piras F, et al. The effects of periodontal treatment on rheumatoid arthritis and of anti-rheumatic drugs on periodontitis: a systematic review. Int J Mol Sci 2023; 24(24): 17228.
  20. Jang S, Kwon E-J, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci 2022; 23(2): 905.
  21. Zare Moghadam M, Ghotloo S. Stem cell-based treatment of rheumatoid arthritis. The First National Student Festival of Stem Cell Science and Technology. Proceedings of the The 1 st National Student Festival of Stem Cell Science and Technology; Ahvaz, Iran; 2022. [in Pertsian].
  22. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012; 11(3): 234-50.
  23. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011; 63(12): 3702-11.
  24. Wang L, Huang S, Li S, Li M, Shi J, Bai W, et al. Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study. Drug Des Devel Ther 2019; 13: 4331-40.
  25. Nell V, Machold K, Eberl G, Stamm T, Uffmann M, Smolen J. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43(7): 906-14.
  26. de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford) 2017; 57(7): 1135-44.
  27. Moura MDG, Lopes LC, Silva MT, Barberato-Filho S, Motta RHL, de Cássia Bergamaschi C. Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol. Medicine (Baltimore) 2018; 97(41): e12658.
  28. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 2018; 6: 15.
  29. Abdelmawgoud H, Saleh A. Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model. Adv Clin Exp Med 2018; 27(7): 873-80.
  30. Lv X, Wang L, Zou X, Huang S. Umbilical cord mesenchymal stem cell therapy for regenerative treatment of rheumatoid arthritis: opportunities and challenges. Drug Des Devel Ther 2021; 15: 3927-36.
  31. Mrid RB, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. Biomed Pharmacother 2022; 151: 113126.
  32. Thakur S, Riyaz B, Patil A, Kaur A, Kapoor B, Mishra V. Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview. Biomed Pharmacother 2018; 106: 1011-23.
  33. Cutolo M, Shoenfeld Y, Bogdanos DP, Gotelli E, Salvato M, Gunkl-Tóth L, et al. To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debate. Autoimmun Rev 2024; 23(1): 103437.
  34. Littlejohn EA, Monrad SU. Early diagnosis and treatment of rheumatoid arthritis. Prim Care 2018; 45(2): 237-55.
  35. Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open 2016; 2(1): e000203.
  36. Sinniah A, Yazid S, Flower RJ. From NSAIDs to glucocorticoids and beyond. Cells 2021; 10(12): 3524.
  37. Shadmanfar S, Labibzadeh N, Emadedin M, Jaroughi N, Azimian V, Mardpour S, et al. Intra-articular knee implantation of autologous bone marrow–derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy 2018; 20(4): 499-506.
  38. Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 2016; 75(8): 1428-37.
  39. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018; 320(13): 1360-72.
  40. Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 2016; 12(12): 731-42.
  41. Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2021; 73(7): 1108-23.
  42. Altawil R, Saevarsdottir S, Wedrén S, Alfredsson L, Klareskog L, Lampa J. Remaining pain in early rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res (Hoboken) 2016; 68(8): 1061-8.
  43. Papadopoli DJ, Ma EH, Roy D, Russo M, Bridon G, Avizonis D, et al. Methotrexate elicits pro-respiratory and anti-growth effects by promoting AMPK signaling. Sci Rep 2020; 10(1): 7838.
  44. Findeisen KE, Sewell J, Ostor AJK. Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. Biologics 2021; 15: 343-52.
  45. Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, et al. Comparative risk of cardiovascular events with biologic and synthetic disease‐modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta‐analysis. Arthritis Care Res (Hoboken) 2020; 72(4): 561-76.
  46. Marona J, Sepriano A, Ramiro S, Almeida D, Brites L, Couto M. Effectiveness of biosimilar infliximab CT-P13 compared to originator infliximab in biological-naïve patients with rheumatoid arthritis and axial spondyloarthritis: data from the Portuguese Register Reuma. pt. ARP Rheumatol ARP Rheumatol 2023; 2(2): 132-40.
  47. Deakin CT, De Stavola BL, Littlejohn G, Griffiths H, Ciciriello S, Youssef P, et al. Comparative effectiveness of adalimumab vs tofacitinib in patients with rheumatoid arthritis in Australia. JAMA Netw Open 2023; 6(6): e2320851.
  48. Xing Q, Fu L, Yu Z, Zhou X. Efficacy and Safety of Integrated Traditional Chinese Medicine and Western Medicine on the Treatment of Rheumatoid Arthritis: A Meta-Analysis. Evid Based Complement Alternat Med 2020; 2020: 4348709.
  49. Akram M, Daniyal M, Sultana S, Owais A, Akhtar N, Zahid R, et al. ETraditional and modern management strategies for rheumatoid arthritis. Clin Chim Acta 2021; 512: 142-55.
  50. Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med 2017; 6(6): 1445-51.
  51. El-Jawhari JJ, El-Sherbiny Y, McGonagle D, Jones E. Multipotent mesenchymal stromal cells in rheumatoid arthritis and systemic lupus erythematosus; from a leading role in pathogenesis to potential therapeutic saviors? Front Immunol 2021; 12: 643170.
  52. Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 2011: 9: 181.
  53. Munir H, McGettrick HM. Mesenchymal stem cell therapy for autoimmune disease: risks and rewards. Stem Cells Dev 2015; 24(18): 2091-100.
  54. Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif 2020; 53(1): e12712.
  55. Chin S-P, Mohd-Shahrizal M-Y, Liyana M-Z, Then KY, Cheong SK. High Dose of Intravenous Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells (CLV-100) Infusion Displays Better Immunomodulatory Effect among Healthy Volunteers: A Phase 1 Clinical Study. Stem Cells Int 2020; 2020(1): 8877003.
  56. Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal Stem Cell Migration and Tissue Repair. Cells 2019; 8(8): 784.
  57. Chen L, Carlton M, Chen X, Kaur N, Ryan H, Parker TJ, et al. Effect of fibronectin, FGF-2, and BMP4 in the stemness maintenance of BMSCs and the metabolic and proteomic cues involved. Stem Cell Res Ther 2021; 12(1): 165.
  58. Liu Y, Mu R, Wang S, Long L, Liu X, Li R, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010; 12(6): R210.
  59. Park EH, Lim H-s, Lee S, Roh K, Seo K-W, Kang K-S, et al. Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial. Stem Cells Transl Med 2018; 7(9): 636-42.
  60. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13(3): 159-75.
  61. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014; 15(11): 1009-16.
  62. Silva LH, Antunes MA, Dos Santos CC, Weiss DJ, Cruz FF, Rocco PR. Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases. Stem Cell Res Ther 2018; 9(1): 45.
  63. El-Zayadi AA, Jones EA, Churchman SM, Baboolal TG, Cuthbert RJ, El-Jawhari JJ, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology (Oxford) 2017; 56(3): 488-93.
  64. Bačenková D, Trebuňová M, Morochovič R, Dosedla E, Findrik Balogová A, Gašparová P, et al. Interaction between mesenchymal stem cells and the immune system in rheumatoid arthritis. Pharmaceuticals (Basel) 2022; 15(8): 941.
  65. Alavi M, Tavakkol-Afshari J, Shariati-Sarabi Z, Shabgah AG, Ghoryani M, Ghasemi A, et al. Intravenous injection of autologous bone marrow-derived mesenchymal stem cells on the gene expression and plasma level of CCL5 in refractory rheumatoid arthritis. J Res Med Sci 2020; 25: 111.
  66. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12(5): 383-96.
  67. El-Jawhari J, El-Sherbiny Y, Jones E, McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM 2014; 107(7): 505-14.
  68. Luz-Crawford P, Djouad F, Toupet K, Bony C, Franquesa M, Hoogduijn MJ, et al. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells 2016; 34(2): 483-92.
  69. Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, et al. Mesenchymal stromal cell–derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008; 112(13): 4991-8.
  70. Schena F, Gambini C, Gregorio A, Mosconi M, Reverberi D, Gattorno M, et al. Interferon‐γ–dependent inhibition of B cell activation by bone marrow–derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 2010; 62(9): 2776-86.
  71. Wang L, Wang L, Cong X, Liu G, Zhou J, Bai B, et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev 2013; 22(24): 3192-202.
  72. Han Y, Yang J, Fang J, Zhou Y, Candi E, Wang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther 2022; 7(1): 92.
  73. Ortiz LA, DuTreil M, Fattman C, Pandey AC, Torres G, Go K, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007; 104(26): 11002-7.
  74. Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Poursamimi J, Mohammadi M. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. Biomed Pharmacother 2019; 109: 1834-40.
  75. Yang Y, He X, Zhao R, Guo W, Zhu M, Xing W, et al. Serum IFN-γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis. J Transl Med 2018; 16(1): 165.
  76. Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghoryani M, Mohammadi M. Possible anti-inflammatory effects of mesenchymal stem cells transplantation via changes in CXCL8 levels in patients with refractory rheumatoid arthritis. Int J Mol Cell Med 2019; 8(3): 191-9.
  77. Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. The Sufficient Immunoregulatory Effect of Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation on Regulatory T Cells in Patients with Refractory Rheumatoid Arthritis. J Immunol Res 2020; 2020: 3562753.
  78. Álvaro-Gracia JM, Jover JA, García-Vicuña R, Carreño L, Alonso A, Marsal S, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis 2017; 76(1): 196-202.
  79. Kafaja S, Segal KR, Skerrett D, Itescu S, Furst DE. FRI0220 Allogeneic mesenchymal precursor cells (MPCS): A novel approach to treating biologic refractory rheumatoid arthritis. Annals of the Rheumatic Diseases 2017; 76(2): 566-7.
  80. Liang J, Li X, Zhang H, Wang D, Feng X, Wang H, et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol 2012; 31(1): 157-61.
  81. Rahimi -Khorashad M, Ghoryani M, Gowhari Shabgah A, Shariati-Sarabi Z, Tavakkol Afshari j, Mohammadi M. The effects of mesenchymal stem cells on the gene expression of tgf-beta and ifn-gamma in patients with rheumatoid arthritis. Iran J Allergy Asthma Immunol 2023; 22(2): 183-9.
  82. Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA) .[cited 2024-12-07]. Availablr from: https://clinicaltrials.gov.
  83. Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis. [cited 07-12-2024]. Available from: https://clinicaltrials.gov.
  84. Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis [cited 2024-12-07]. Available from: https://clinicaltrials.gov.
  85. A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor. [cited 2024-12-07]. Available from: https://clinicaltrials.gov.
  86. Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis .[cited2024]. Available from:https://clinicaltrials.gov/study/NCT038283442024.
  87. The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients [cited 2024]. Available from: https://clinicaltrials.gov.
  88. Mesenchymal Stem Cells in Early Rheumatoid Arthritis. [cited 2024-12-07]. Available from: https://clinicaltrials.gov.
  89. Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis. [cited 2024-12-07]. Available from: https://clinicaltrials.gov.
  90. The Safety and Effects of Mesenchymal Stem Cell (MSCs) in the Treatment of Rheumatoid Arthritis. [cited 2024-12-07]. Available from: https://clinicaltrials.gov.
  91. Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA. [cited 2024-12-07].Available from: https://clinicaltrials.gov.
  92. Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis.[cited 2022]. Available from: https://clinicaltrials.gov/study/NCT036187842024.
  93. Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis.[cited 2022]. Available from: https://clinicaltrials.gov/study/NCT030678702022-022024.
  94. Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis (RA) .[cited 2014-12]. Available from :https://clinicaltrials.gov/study/NCT015470912024.
  95. Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis (HB-adMSCs).[cited 2020-09-28]. Available from: https://clinicaltrials.gov/study/NCT03691909.
  96. Yang JH, Liu FX, Wang JH, Cheng M, Wang SF, Xu DH. Mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles: Potential roles in rheumatic diseases. World J Stem Cells 2020; 12(7): 688-705.
  97. Lui PPY, Leung YT. Practical Considerations for Translating Mesenchymal Stromal Cell-Derived Extracellular Vesicles from Bench to Bed. Pharmaceutics 2022; 14(8): 1684.
  98. Tang J, Wang X, Lin X, Wu C. Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases. Cell Death Discov 2024; 10(1): 212.
  99. Huang C-C, Kang M, Leung K, Lu Y, Shirazi S, Gajendrareddy P, et al. Micro RNA based MSC EV engineering: Targeting the BMP2 cascade for bone repair Front Cell Dev Biol 2023; 11: 1127594.
  100. Matthay MA. Extracellular Vesicle Transfer from Mesenchymal Stromal Cells Modulates Macrophage Function in Acute Lung Injury. Basic Science and Clinical Implications. Am J Respir Crit Care Med 2017; 196(10): 1234-6.
  101. Casado JG, Blázquez R, Vela FJ, Álvarez V, Tarazona R, Sánchez-Margallo FM. Mesenchymal Stem Cell-Derived Exosomes: Immunomodulatory Evaluation in an Antigen-Induced Synovitis Porcine Model. Front Vet Sci 2017; 4: 39.
  102. Sharma J, Hampton JM, Valiente GR, Wada T, Steigelman H, Young MC, et al. Therapeutic Development of Mesenchymal Stem Cells or Their Extracellular Vesicles to Inhibit Autoimmune-Mediated Inflammatory Processes in Systemic Lupus Erythematosus. Front Immunol 2017; 8: 526.
  103. Duong A, Parmar G, Kirkham AM, Burger D, Allan DS. Registered clinical trials investigating treatment with cell-derived extracellular vesicles: a scoping review. Cytotherapy 2023; 25(9): 939-45.
  104. Miao H-b, Wang F, Lin S, Chen Z. Update on the role of extracellular vesicles in rheumatoid arthritis. Expert Rev Mol Med 2022; 24: e12.
  105. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant 2016; 25(5): 829-48.
  106. Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K. Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int 2019; 2019(1): 9628536.
  107. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014; 32(3): 252-60.
  108. Roodenrijs NMT, Kedves M, Hamar A, Nagy G, van Laar JM, van der Heijde D, et al. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open 2021; 7(1): e001511.
  109. Del Grossi Moura M, Cruz Lopes L, Silva MT, Barberato-Filho S, Motta RHL, Bergamaschi CC. Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol. Medicine (Baltimore) 2018; 97(41): e12658.
  110. Hu C, Li L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. J Cell Mol Med 2018; 22(3): 1428-42.
  111. Raziyeva K, Smagulova A, Kim Y, Smagul S, Nurkesh A, Saparov A. Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment. Int J Mol Sci 2020; 21(19): 7301.
  112. Saparov A, Ogay V, Nurgozhin T, Jumabay M, Chen WC. Preconditioning of Human Mesenchymal Stem Cells to Enhance Their Regulation of the Immune Response. Stem Cells Int 2016; 2016: 3924858.
  113. Mansurov N, Chen WCW, Awada H, Huard J, Wang Y, Saparov A. A controlled release system for simultaneous delivery of three human perivascular stem cell-derived factors for tissue repair and regeneration. J Tissue Eng Regen Med 2018; 12(2): e1164-e72.
  114. Park JS, Suryaprakash S, Lao YH, Leong KW. Engineering mesenchymal stem cells for regenerative medicine and drug delivery. Methods 2015; 84: 3-16.
  115. Noronha NdC, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha JLM, Covas DT, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther 2019; 10(1): 131.
  116. Chen W, Lv L, Chen N, Cui E. Immunogenicity of mesenchymal stromal/stem cells. Scand J Immunol 2023; 97(6): e13267.
  117. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014; 32(3): 252-60.
  118. Oliveira RL, Chagastelles PC, Sesterheim P, Pranke P. In Vivo Immunogenic Response to Allogeneic Mesenchymal Stem Cells and the Role of Preactivated Mesenchymal Stem Cells Cotransplanted with Allogeneic Islets. Stem Cells Int 2017; 2017: 9824698.
  119. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16(9): 2094-103.
  120. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67(19): 9142-9.
  121. Zhang L, Xiang J, Zhang F, Liu L, Hu C. MSCs can be a double-edged sword in tumorigenesis. Front Oncol 2022; 12: 1047907.
  122. Jouybari MT, Mojtahedi F, Babaahmadi M, Faeed M, Eslaminejad MB, Taghiyar L. Advancements in extracellular vesicle targeted therapies for rheumatoid arthritis: insights into cellular origins, current perspectives, and emerging challenges. Stem Cell Res Ther 2024; 15(1): 276
  123. Alcaraz MJ, Guillén MI. Cellular and Molecular Targets of Extracellular Vesicles from Mesenchymal Stem/Stromal Cells in Rheumatoid Arthritis. Stem Cells Transl Med 2022; 11(12): 1177-85.
مجله دانشکده پزشکی اصفهان
دوره 43، شماره 822
هفته 2، شهریور
مرداد و شهریور 1404
صفحه 804-818

فایل ها

سابقه مقاله

  • تاریخ دریافت: 14 بهمن 1403
  • تاریخ پذیرش: 09 مهر 1404

هم رسانی

ارجاع به این مقاله

آمار